- Record: found
- Abstract: not found
- Article: not found
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu ,
Richard S Finn ,
Julien Edeline ,
Stephane Cattan ,
Sadahisa Ogasawara ,
Daniel Palmer ,
Chris Verslype ,
Vittorina Zagonel ,
Laetitia Fartoux ,
Arndt Vogel ,
Debashis Sarker ,
Gontran Verset ,
Stephen L Chan ,
Jennifer Knox ,
Bruno Daniele ,
Andrea L Webber ,
Scot W Ebbinghaus ,
Junshui Ma ,
Abby B Siegel ,
Ann-Lii Cheng ,
Masatoshi Kudo ,
Angela Alistar ,
Jamil Asselah ,
Jean-Frederic Blanc ,
Ivan Borbath ,
Timothy Cannon ,
Ki Chung ,
Allen Cohn ,
David P Cosgrove ,
Nevena Damjanov ,
Mukul Gupta ,
Yoshivasu Karino ,
Mark Karwal ,
Andreas Kaubisch ,
Robin Kelley ,
Jena-Luc Van Laethem ,
Timothy Larson ,
James Lee ,
Daneng Li ,
Atisha Manhas ,
Gulam Abbas Manji ,
Kazushi Numata ,
Benjamin Parsons ,
Andrew S. Paulson ,
Carmine Pinto ,
Robert Ramirez ,
Suresh Ratnam ,
Magnus Rizell ,
Olivier Rosmorduc ,
Yvonne Sada ,
Yutaka Sasaki ,
Per I Stal ,
Simone Strasser ,
Joerg Trojan ,
Gina Vaccaro ,
Hans Van Vlierberghe ,
Alan Weiss ,
Karl-Heinz Weiss ,
Tatsuya Yamashita
July 2018
July 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Immune checkpoint blockade therapy has shown promising results in patients with advanced
hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab
in this patient population.